Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grail Raises $390M In Series D Financing To Advance Blood Cancer Test

Executive Summary

Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.

You may also be interested in...



Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021

Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.

Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test

Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.     

2020 VC Landscape: Reviewing The First Six Months

A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel